# The Oral GLP-1 UK Market: Wegovy Tablet, Orforglipron and What’s Coming
The UK obesity treatment landscape changed permanently on 11 June 2026, when the MHRA approved oral semaglutide for weight management — the first oral GLP-1 medicine licensed in the UK specifically for obesity. Within the next 18 months, a second oral GLP-1 product is expected to seek regulatory approval. The shift from injection-dominated to tablet-accessible treatment is underway, and it matters for millions of people who were never comfortable with weekly self-injection.
This article maps the UK oral GLP-1 market as it stands now, what is coming, and what the next 18 months might look like for patients, providers, and the broader market.
> Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting or changing treatment.
—
## What is already available: Wegovy tablet and Rybelsus
Two oral semaglutide products are currently licensed in the UK, and they are frequently confused.
**Wegovy tablet (oral semaglutide 25mg)** — approved by the MHRA on 11 June 2026 for weight management in adults with BMI 30+, or BMI 27+ with a weight-related comorbidity. This is the medicine this site tracks. Seven UK providers are taking pre-orders at prices from £64/month for the 1.5mg starting dose. Commercial stock is expected from July 2026.
**Rybelsus (oral semaglutide 3mg/7mg/14mg)** — also made by Novo Nordisk, also oral semaglutide, but licensed specifically for type 2 diabetes management, not for weight loss or obesity. Rybelsus is prescribed to people with diabetes to improve blood sugar control, and secondarily tends to cause some weight loss. It is not a weight management product under its UK licence, cannot be prescribed legally for weight loss in the UK, and is a completely different commercial product to Wegovy tablet despite containing the same active ingredient. It is available on the NHS for diabetes patients.
This distinction matters because some online pharmacies and comparison sites conflate the two. If you are looking for an oral medication for weight management, only Wegovy tablet (oral semaglutide, licensed for weight management) is relevant.
—
## What is coming: orforglipron (Eli Lilly, expected ~2027)
The next oral GLP-1 to watch is orforglipron — Eli Lilly’s small-molecule GLP-1 receptor agonist, currently completing its regulatory submission process following successful Phase 3 trial results.
Orforglipron differs from oral semaglutide in two important ways:
**No fasting requirement.** Oral semaglutide must be taken 30 minutes before food or drink (other than plain water, maximum 120ml). Orforglipron, as a small molecule rather than a peptide, does not require this restriction and can be taken without regard to meals. This is a practical advantage for a proportion of patients.
**Different trial data.** Orforglipron’s Phase 3 programme (the ATTAIN trials) showed approximately 9–10% average weight loss at 36 weeks at the highest studied dose. Direct comparison with oral semaglutide is not straightforward due to different trial durations, populations, and dose schedules — but both medicines produce clinically meaningful weight loss.
Eli Lilly has not confirmed a UK submission date, but regulatory analysts expect an MHRA application in late 2026, with a decision possible in 2027. Private prescription access would begin from the approval date, assuming commercial supply is in place. NHS access would require a separate NICE appraisal — likely 2028 at the earliest.
—
## The broader oral GLP-1 pipeline
Beyond orforglipron, the next 12–36 months may bring further oral GLP-1 options to the UK market. Several pharmaceutical companies — including AstraZeneca and Pfizer — have oral GLP-1 candidates at various stages of clinical development, though none are as far advanced as orforglipron as of mid-2026.
The long-term direction of travel is clear: the weight management medication market is moving from injectable to oral. The annual market for weight loss medications globally is projected to reach hundreds of billions of dollars by 2030. The UK market, while smaller, follows the same trajectory.
—
## What this means for the UK patient population
Current estimates suggest between 12–15 million adults in England alone live with obesity (BMI 30+). Injectable Wegovy has been available privately since 2023, but its weekly injection requirement has limited adoption to patients willing and able to self-inject. The addition of an oral option is expected to significantly expand the addressable patient population.
If NHS access follows — which requires a positive NICE recommendation for oral Wegovy, not yet initiated — the scale of uptake could be transformative. The NHS currently spends approximately £3.4 billion annually on the consequences of obesity across the health system. Even a modest reduction in obesity prevalence could generate significant downstream savings.
For now, private prescription remains the only route. With seven providers offering pre-orders and prices from £64/month at the starting dose, access has expanded considerably beyond what was available for injectable Wegovy at the equivalent stage of its UK launch.
—
## What to expect over the next 18 months
– **July 2026:** First commercial stock dispatched; pre-order patients begin receiving tablets
– **Late 2026:** Higher-dose (9mg, 25mg) pricing established as early patients progress up the escalation schedule; new providers enter the market; potential first price movements downward
– **2027:** Orforglipron expected to submit to MHRA; potential approval and private prescription launch; significant competitive pressure on oral semaglutide pricing
– **2028+:** NICE evaluation timelines for both oral semaglutide and orforglipron; potential NHS access decisions
—
## Stay ahead of the market
CompareWegovyPrices.co.uk tracks all 80 UK providers, regulatory developments, and the broader oral GLP-1 landscape in real time. We are the only dedicated tracker for this market.
[Compare Wegovy tablet pre-order prices →](/providers/)
[Sign up for market updates and price alerts →](/providers/)
—
*This article is for informational purposes only and does not constitute medical advice. Wegovy tablets are a prescription-only medicine. Always consult a qualified healthcare professional before starting treatment. CompareWegovyPrices.co.uk is not affiliated with Novo Nordisk or Eli Lilly.*
